Novel Strategies in the Prevention/Treatment of Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 3195
Special Issue Editors
Interests: fluoropyrimidine; colorectal cancer; thymidylate synthase; DNA topoisomerase 1; DNA repair
Special Issues, Collections and Topics in MDPI journals
Interests: colon and rectal cancer; drug discovery; experimental therapeutics
Special Issue Information
Dear Colleagues,
The signaling pathways dysregulated during canonical CRC initiation and progression are potential targets for both chemoprevention and cancer treatment. However, the Wnt, P53, and TGF-b pathways have not been fully exploited for drug development to either reduce CRC incidence or improve treatment, in part because of their key role in normal tissue homeostasis and the difficulty in developing drugs for these targets. Chemoprevention of CRC for high-risk individuals (e.g., Lynch syndrome) is still under development, but with promising preclinical results targeting mediators of inflammation such as COX-2 and other targets such as HMG-CoA reductase. Cancer interception is a new strategy for which target pathway identification is in its infancy. In contrast, adjuvant chemotherapy for locally advanced CRC uses fluoropyrimidine combinations such as FOLFOX to target TS and DNA damage, while treatment of metastatic disease may use these same combinations of drugs or antibodies targeting EGFR, VEGF, and more recently BRAF and KRAS, but innovative strategies continue to be developed to personalize the therapeutic approach.
The current Special Issue will focus on original research articles and comprehensive reviews illuminating the most recent advances in understanding molecular pathways of CRC initiation and progression that are amenable to therapeutic intervention. Studies identifying and validating novel pathways or targets for preventing or treating CRC are of special interest; however, innovative approaches for well-validated targets for CRC therapy including TS, DNA topoisomerase 1, EGFR, and other targets are also of interest. Innovative approaches to use chemotherapy in combination with immunotherapy and for the development of cancer vaccines are of special interest.
Prof. Dr. William H. Gmeiner
Prof. Dr. Dan A. Dixon
Prof. Dr. Margie Lee Clapper
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- chemotherapy
- chemoprevention
- targeted therapy
- kinase inhibitor
- immunotherapy
